November 16th, 2026Diabetes Dialogue: Tubeless Mobi Clearance, CGM Choice, and Eversense FreedomDiana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.Read more
November 16th, 2026Diabetes Dialogue: OPTIMAL-DIABETES, Survodutide, and Orforglipron at AHA 2026Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.Read more
November 12th, 2026Diabetes Dialogue: Retatrutide Tops Semaglutide on A1C, Weight in T2DTRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.Read more
November 12th, 2026Diabetes Dialogue: CONNECT Trial Backs CGM in Non-Insulin Type 2 DiabetesTom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.Read more
November 9th, 2026The HCPFive: Top News for Healthcare Providers from the Week of 11/1Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.Read more
November 18th, 2026Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics. Read more
November 18th, 2026RENEW: Blinded Interim Data Show FVC Trends With LTI-03 in IPFPooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.Read more
November 17th, 2026Don't Miss a Beat: How Prediction Markets Could Threaten Clinical Trial IntegrityAnkeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.Read more